Clinical Trials Sponsored by Astellas Pharma US, Inc

Total 1235 results

Astellas Pharma Inc

Completed

Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Chronic Kidney Disease

Japan
Astellas Pharma Inc

Completed

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Overactive Bladder (OAB)

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation

Chronic Constipation

Japan
Astellas Pharma Inc

Completed

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients (STELLALONGTERM)

Type 2 Diabetes

Japan
Astellas Pharma Inc

Completed

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

Urinary Bladder, Overactive

Sweden, United Kingdom, Belgium, Denmark
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Astellas Pharma Inc

Completed

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

Chronic Kidney Disease | Hyperphosphatemia Undergoing Hemodialysis

Japan
Astellas Pharma Inc

Completed

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Astellas Pharma Inc

Completed

Special Drug Use Surveillance of Irribow in Female Patients

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate

Rheumatoid Arthritis

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects

Healthy Volunteers

Japan
Astellas Pharma Inc

Completed

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile

Japan
Astellas Pharma Inc

Terminated

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Korea, Republic of, Belgium, United States, Hong Kong, Singapore, Taiwan, Germany, Spain, France, Italy
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Urinary Incontinence

United States, Canada
Astellas Pharma Inc

Completed

A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Candidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal Candidiasis

United States, South Africa
Astellas Pharma Inc

Completed

Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch (LIFT)

or Peripheral Nerve Injury (PNI) | Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)

Belgium, Czechia, Denmark, Ireland, Norway, Slovakia, United Kingdom
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

Study of FK463 for the Treatment of Invasive Aspergillosis

Aspergillosis

United Kingdom, Austria, France, Germany, Italy, Poland, Spain, Sweden
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
Astellas Pharma Inc

Completed

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (TAURUS)

Urinary Bladder, Overactive

Canada, Poland, Belgium, Spain, Sweden, United States, Romania, Italy, France, Austria, United Kingdom, Germany, Hungary, Australia, Denmark, Netherlands, Switzerland, Lithuania, Russian Federation, Latvia, South Africa, Slovakia, F... and more
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Astellas Pharma Inc

Completed

Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation (DIAMOND)

Liver Transplantation

Argentina, Austria, Belarus, Belgium, Brazil, Canada, Colombia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Switzerland, United Kingdom
Astellas Pharma Inc

Completed

A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection (OSAKA)

Kidney Transplantation

Belgium, France, Germany, Italy, Spain, Greece, Switzerland, United Kingdom, Ireland, South Africa, Romania, Sweden, Russian Federation, Austria, Hungary, Poland, Portugal, Netherlands, Argentina, Czechia, Norway, Slovakia
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation (MAIN)

Liver Transplantation

Korea, Republic of
Astellas Pharma Inc

Completed

Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys (TIGRE)

KIDNEY TRANSPLANTATION

Italy
Astellas Pharma Inc

Completed

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

Fungemia | Fungal Infections

China
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients

De Novo Kidney Transplantation

Belgium, France, Netherlands, Spain, Sweden, Austria, Italy, Germany, United Kingdom, Hungary, Poland, Czech Republic
Astellas Pharma Inc

Completed

Reproducibility Study of OABSS and Its Response to Treatment (RESORT part 2)

Overactive Bladder

Thailand
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

Kidney Transplantation

United States
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN) (STEP)

Pain | Diabetic Peripheral Neuropathy

United States
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules

Healthy | Urine Phosphorus Excretion

Japan
Astellas Pharma Inc

Completed

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Prostate Cancer | Tumors

United States
Astellas Pharma Inc

Completed

A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects

Pharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male Subjects

Japan
Astellas Pharma Inc

Completed

A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia

Functional Dyspepsia | Dyspepsia

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

Post Operative Pain

Japan
Astellas Pharma Inc

Completed

Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis

Dermatitis, Atopic

United States
Astellas Pharma Inc

Completed

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Candidemia | Candidiasis

Belgium, France, Germany, Spain, United States, India, Canada, Brazil, Switzerland, Austria, Croatia, Netherlands, Poland, Czech Republic, United Kingdom
Astellas Pharma Inc

Completed

Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis

Dermatitis

United States
Astellas Pharma Inc

Completed

Long-term Safety of Protopic in Atopic Eczema

Dermatitis, Atopic | Eczema, Atopic

France, Germany, United Kingdom, Spain, Belgium, Netherlands, Finland, Poland, Ireland, Hungary, Denmark, Latvia
Astellas Pharma Inc

Completed

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder (VERSUS)

Urinary Bladder, Overactive

United States
Astellas Pharma Inc

Completed

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. (VICTOR)

Urinary Incontinence

United States
Astellas Pharma Inc

Completed

Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis

Atopic Dermatitis

Australia, Belgium, Poland, Hungary, Portugal, Germany, Iceland, Malta
Astellas Pharma Inc

Completed

Solifenacin Succinate Versus Tolterodine 4mg Once Daily (STAR)

Urinary Bladder, Overactive

France, United Kingdom, Spain, Belarus, Belgium, Ukraine, Denmark, Greece, Russian Federation, Czech Republic, Netherlands, Germany, Hungary, Italy, Slovakia, Sweden, Norway

Clinical Trials Sponsored by Astellas Pharma US, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations